Date Insider Type Main position Quantity % Market Cap.
06/03/22Tender

Chief Technology Officer

377,396 0.6724%
06/03/22Tender

Chief Executive Officer

977,754 1.7421%
06/03/22Tender

Director

80,277 0.1430%
Change 5-day change 1-year change 3-year change Capi.($)
+1.60%+1.60% - - 1.5B
-0.53%+1.67%+19.19%-20.47% 63.09B
-0.47%+2.28%+51.30%+215.54% 55.61B
+0.07%+38.60%+38.60%+38.60% 41.64B
-2.36%-1.25%-52.13%-58.98% 38.98B
+1.19%+2.74%+58.64%-29.02% 29.82B
-1.11%-6.58%+122.45%-49.58% 23.71B
-0.86%+9.48%+59.19%+72.19% 21.48B
-1.25%-0.27%-4.39%+142.42% 16.87B
-2.23%+3.24%+65.18%+120.77% 16.74B
Average -0.55%+2.98%+39.78%+47.94% 34.22B
Weighted average by Cap. -0.66%+2.91%+34.35%+45.26%
Logo Zogenix, Inc.
Zogenix Inc is a United States-based biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for rare diseases. It is primarily focused on developing and commercializing two therapeutic product opportunities: Fintepla and MT1621. Its first rare disease therapy, Fintepla is an oral solution, developed for the treatment of seizures associated with Dravet syndrome, a rare, devastating, severe lifelong epilepsy. The Company also has two late-stage development programs underway, one for Fintepla for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare childhood-onset epilepsy. MT1621 is an investigational deoxynucleoside-combination substrate enhancement therapy in development for the treatment of TK2d, an inherited mitochondrial deoxyribonucleic acid depletion disease that predominantly affects children and is often fatal.
Employees
327
  1. Stock Market
  2. Stocks
  3. ZGNX Stock